Key statistics
On Friday, MannKind Corp (MNKD:NMQ) closed at 7.35, -3.74% below its 52-week high of 7.63, set on Nov 06, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6.99 |
---|---|
High | 7.35 |
Low | 6.61 |
Bid | 7.30 |
Offer | 7.35 |
Previous close | 7.39 |
Average volume | 3.38m |
---|---|
Shares outstanding | 275.00m |
Free float | 269.12m |
P/E (TTM) | 204.77 |
Market cap | 2.02bn USD |
EPS (TTM) | 0.0359 USD |
Data delayed at least 15 minutes, as of Nov 08 2024 21:15 GMT.
More ▼
- MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update
- MannKind to Present at 2024 UBS Healthcare Conference
- MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases
- MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024
- More Adults With Type 1 Diabetes Achieved A1C Goal (<7%) After Switching From Multiple Daily Insulin Injections or Automated Pumps to Inhaled Insulin (Afrezza®)
- MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
- MannKind to Present at 2024 Cantor Fitzgerald Global Healthcare Conference
- MannKind to Present at Upcoming Conferences
- Kent Kresa to Retire from MannKind’s Board of Directors; Steven B. Binder to be Appointed to the Board
- MannKind Corporation Reports 2024 Second Quarter Financial Results: Provides Clinical Development Update
More ▼